Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...
eLife

Functional analysis across model systems implicates ribosomal proteins in growth and proliferation defects associated with hypoplastic left heart syndrome

Cross-species functional genomics identify ribosomal protein genes as key regulators of cardiomyocyte proliferation and heart development, implicating them as candidate modifiers for HLHS and ...

DNAe Unveils Early Access Program for LiDia--SEQ(TM): Hospital Teams Invited to Trial DNAe's Flagship Tests and Preview DNAe's Innovative NGS Diagnostic Platform

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...